FDA Clears Tezacaftor/Ivacaftor Combo for Cystic Fibrosis FDA Clears Tezacaftor/Ivacaftor Combo for Cystic Fibrosis

Symdeko is for people aged 12 years and older who have two copies of the F508del mutation in the CFTR gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor.FDA Approvals
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Pulmonary Medicine News Alert Source Type: news